[1]
|
段永建, 易群. 肺动脉高压病因及治疗研究进展[J]. 西部医学, 2016, 28(8): 1178-1180+1185.
|
[2]
|
杨杏, 叶瑞华, 周丽芹. 肺动脉高压患者的病因构成与肺动脉压力因素[J]. 华夏医学, 2020, 33(4): 67-70. https://doi.org/10.19296/j.cnki.1008-2409.2020-04-018
|
[3]
|
万钧, 翟振国. 肺动脉高压临床诊治和管理中需要关注的热点问题——基于《2022 ESC/ERS肺动脉高压诊治指南》与《中国肺动脉高压诊断与治疗指南(2021版)》的比较与解读[J]. 中国全科医学, 2023, 26(3): 255-261+267.
|
[4]
|
Mocumbi, A., Humbert, M., Saxena, A., Jing, Z., Sliwa, K., Thienemann, F., et al. (2024) Pulmonary Hypertension. Nature Reviews Disease Primers, 10, Article No. 1. https://doi.org/10.1038/s41572-023-00486-7
|
[5]
|
Liu, S., Nambiar Veetil, N., Li, Q., Kucherenko, M.M., Knosalla, C. and Kuebler, W.M. (2022) Pulmonary Hypertension: Linking Inflammation and Pulmonary Arterial Stiffening. Frontiers in Immunology, 13, Article ID: 959209. https://doi.org/10.3389/fimmu.2022.959209
|
[6]
|
Rabinovitch, M., Guignabert, C., Humbert, M. and Nicolls, M.R. (2014) Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial Hypertension. Circulation Research, 115, 165-175. https://doi.org/10.1161/circresaha.113.301141
|
[7]
|
Evans, C.E., Cober, N.D., Dai, Z., Stewart, D.J. and Zhao, Y. (2021) Endothelial Cells in the Pathogenesis of Pulmonary Arterial Hypertension. European Respiratory Journal, 58, Article ID: 2003957. https://doi.org/10.1183/13993003.03957-2020
|
[8]
|
Balistrieri, A., Makino, A. and Yuan, J.X. (2023) Pathophysiology and Pathogenic Mechanisms of Pulmonary Hypertension: Role of Membrane Receptors, Ion Channels, and Ca2+ Signaling. Physiological Reviews, 103, 1827-1897. https://doi.org/10.1152/physrev.00030.2021
|
[9]
|
Hassoun, P.M. (2021) Pulmonary Arterial Hypertension. New England Journal of Medicine, 385, 2361-2376. https://doi.org/10.1056/nejmra2000348
|
[10]
|
任成山, 卞士柱, 胡明冬. 肺动脉高压的成因及治疗新理念[J]. 中华肺部疾病杂志(电子版), 2023, 16(1): 1-5.
|
[11]
|
刘思言, 崔狄宇, 陈运清. 肺动脉高压相关病理机制的研究进展[J]. 现代医药卫生, 2024, 40(2): 288-292.
|
[12]
|
樊芳芳, 施熠炜. 《中国肺动脉高压诊断与治疗指南(2021版)》解读: 肺动脉高压诊断流程[J]. 国际呼吸杂志, 2022, 42(5): 326-331.
|
[13]
|
Ruopp, N.F. and Cockrill, B.A. (2022) Diagnosis and Treatment of Pulmonary Arterial Hypertension. JAMA, 327, 1379-1391. https://doi.org/10.1001/jama.2022.4402
|
[14]
|
Humbert, M., Kovacs, G., Hoeper, M.M., Badagliacca, R., Berger, R.M.F., Brida, M., et al. (2022) 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. European Respiratory Journal, 61, Article ID: 2200879. https://doi.org/10.1183/13993003.00879-2022
|
[15]
|
Hoeper, M.M., Pausch, C., Olsson, K.M., Huscher, D., Pittrow, D., Grünig, E., et al. (2021) COMPERA 2.0: A Refined Four-Stratum Risk Assessment Model for Pulmonary Arterial Hypertension. European Respiratory Journal, 60, Article ID: 2102311. https://doi.org/10.1183/13993003.02311-2021
|
[16]
|
Andre, P., Joshi, S.R., Briscoe, S.D., Alexander, M.J., Li, G. and Kumar, R. (2022) Therapeutic Approaches for Treating Pulmonary Arterial Hypertension by Correcting Imbalanced TGF-β Superfamily Signaling. Frontiers in Medicine, 8, Article ID: 814222. https://doi.org/10.3389/fmed.2021.814222
|
[17]
|
Yung, L., Yang, P., Joshi, S., Augur, Z.M., Kim, S.S.J., Bocobo, G.A., et al. (2020) ACTRIIA-Fc Rebalances Activin/GDF versus BMP Signaling in Pulmonary Hypertension. Science Translational Medicine, 12, eaaz5660. https://doi.org/10.1126/scitranslmed.aaz5660
|
[18]
|
Joshi, S.R., Liu, J., Bloom, T., Karaca Atabay, E., Kuo, T., Lee, M., et al. (2022) Sotatercept Analog Suppresses Inflammation to Reverse Experimental Pulmonary Arterial Hypertension. Scientific Reports, 12, Article No. 7803. https://doi.org/10.1038/s41598-022-11435-x
|
[19]
|
Hoeper, M.M., Badesch, D.B., Ghofrani, H.A., Gibbs, J.S.R., Gomberg-Maitland, M., McLaughlin, V.V., et al. (2023) Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 388, 1478-1490. https://doi.org/10.1056/nejmoa2213558
|
[20]
|
Hennigs, J.K., Cao, A., Li, C.G., Shi, M., Mienert, J., Miyagawa, K., et al. (2021) PPARγ-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension. Circulation Research, 128, 401-418. https://doi.org/10.1161/circresaha.119.316339
|
[21]
|
Tang, L., Cai, Q., Wang, X., Li, X., Li, X., Chen, L., et al. (2023) Canagliflozin Ameliorates Hypobaric Hypoxia-Induced Pulmonary Arterial Hypertension by Inhibiting Pulmonary Arterial Smooth Muscle Cell Proliferation. Clinical and Experimental Hypertension, 45, Article ID: 2278205. https://doi.org/10.1080/10641963.2023.2278205
|
[22]
|
He, Y., Zuo, C., Jia, D., Bai, P., Kong, D., Chen, D., et al. (2020) Loss of DP1 Aggravates Vascular Remodeling in Pulmonary Arterial Hypertension via mTORC1 Signaling. American Journal of Respiratory and Critical Care Medicine, 201, 1263-1276. https://doi.org/10.1164/rccm.201911-2137oc
|
[23]
|
Kurosawa, R., Satoh, K., Kikuchi, N., Kikuchi, H., Saigusa, D., Al-Mamun, M.E., et al. (2019) Identification of Celastramycin as a Novel Therapeutic Agent for Pulmonary Arterial Hypertension. Circulation Research, 125, 309-327. https://doi.org/10.1161/circresaha.119.315229
|
[24]
|
Sitbon, O., Bosch, J., Cottreel, E., Csonka, D., de Groote, P., Hoeper, M.M., et al. (2019) Macitentan for the Treatment of Portopulmonary Hypertension (PORTICO): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 4 Trial. The Lancet Respiratory Medicine, 7, 594-604. https://doi.org/10.1016/s2213-2600(19)30091-8
|
[25]
|
Grünig, E., Jansa, P., Fan, F., Hauser, J.A., Pannaux, M., Morganti, A., et al. (2024) Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 83, 473-484. https://doi.org/10.1016/j.jacc.2023.10.045
|
[26]
|
Ciarka, A., Doan, V., Velez-Roa, S., Naeije, R. and van de Borne, P. (2010) Prognostic Significance of Sympathetic Nervous System Activation in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 181, 1269-1275. https://doi.org/10.1164/rccm.200912-1856oc
|
[27]
|
Velez-Roa, S., Ciarka, A., Najem, B., Vachiery, J., Naeije, R. and van de Borne, P. (2004) Increased Sympathetic Nerve Activity in Pulmonary Artery Hypertension. Circulation, 110, 1308-1312. https://doi.org/10.1161/01.cir.0000140724.90898.d3
|
[28]
|
Maron, B.A. and Leopold, J.A. (2015) Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension. Circulation, 131, 2079-2091. https://doi.org/10.1161/circulationaha.114.006980
|
[29]
|
Zhang, H., Wei, Y., Zhang, C., Yang, Z., Kan, J., Gu, H., et al. (2022) Pulmonary Artery Denervation for Pulmonary Arterial Hypertension. JACC: Cardiovascular Interventions, 15, 2412-2423. https://doi.org/10.1016/j.jcin.2022.09.013
|
[30]
|
张璐, 卞士柱. 肺动脉高压患者药物治疗依从性及健康管理分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(1): 107-109.
|
[31]
|
叶瑞华, 杨杏, 高洁, 等. 肺动脉高压的临床特点及呼吸道护理管理对患者预后的影响分析[J]. 现代诊断与治疗, 2020, 31(16): 2648-2649.
|